Shlomo Yanai's most recent trade in Philip Morris International Inc was a trade of 1,002 Common Stock done at an average price of $174.8 . Disclosure was reported to the exchange on May 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Philip Morris | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 174.82 per share. | 07 May 2025 | 1,002 | 8,759 (0%) | 0% | 174.8 | 175,170 | Common Stock |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2025 | 40,258 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2025 | 40,258 | 285,985 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2025 | 34,819 | 34,819 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2024 | 76,453 | 245,727 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2024 | 76,453 | 0 | - | - | Restricted Stock Units | |
| Philip Morris | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 97.84 per share. | 08 May 2024 | 1,789 | 7,501 (0%) | 0% | 97.8 | 175,036 | Common Stock |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2024 | 40,258 | 40,258 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2023 | 80,128 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2023 | 80,128 | 169,274 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2023 | 76,453 | 76,453 | - | - | Restricted Stock Units | |
| Philip Morris | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 96.58 per share. | 03 May 2023 | 1,812 | 5,506 (0%) | 0% | 96.6 | 175,003 | Common Stock |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2022 | 80,128 | 80,128 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2022 | 35,406 | 89,146 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 May 2022 | 35,406 | 0 | - | - | Restricted Stock Units | |
| Philip Morris | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 99.53 per share. | 04 May 2022 | 1,759 | 3,598 (0%) | 0% | 99.5 | 175,073 | Common Stock |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 46,218 | 53,740 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 46,218 | 0 | - | - | Restricted Stock Units | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 35,406 | 35,406 | - | - | Restricted Stock Units | |
| Philip Morris | Shlomo Yanai | Director | Grant, award, or other acquisition of securities at price $ 95.18 per share. | 05 May 2021 | 1,839 | 1,839 (0%) | 0% | 95.2 | 175,027 | Common Stock |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 7,522 | 7,522 (0%) | 0% | - | Class A Common Stock | |
| Amneal Pharmaceuticals Inc... | Shlomo Yanai | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 7,522 | 0 | - | - | Restricted Stock Units |